These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 18823406)

  • 1. Masitinib is safe and effective for the treatment of canine mast cell tumors.
    Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
    J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Masitinib" is safe and effective for the treatment of canine mast cell tumors.
    Gentilini F
    J Vet Intern Med; 2010; 24(1):6; author reply 7. PubMed ID: 20391634
    [No Abstract]   [Full Text] [Related]  

  • 3. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
    Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
    Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
    Devine L; Polzin DJ
    Can Vet J; 2016 Jul; 57(7):752-6. PubMed ID: 27429464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
    Grant J; North S; Lanore D
    J Small Anim Pract; 2016 Jun; 57(6):283-90. PubMed ID: 27136424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
    Miller RL; Van Lelyveld S; Warland J; Dobson JM; Foale RD
    Vet Comp Oncol; 2016 Dec; 14(4):361-370. PubMed ID: 25223579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
    Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
    Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
    BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
    Hahn KA; Legendre AM; Shaw NG; Phillips B; Ogilvie GK; Prescott DM; Atwater SW; Carreras JK; Lana SE; Ladue T; Rusk A; Kinet JP; Dubreuil P; Moussy A; Hermine O
    Am J Vet Res; 2010 Nov; 71(11):1354-61. PubMed ID: 21034327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
    Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
    Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ
    J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
    Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors.
    Spugnini EP; Vincenzi B; Baldi F; Citro G; Baldi A
    Anticancer Res; 2006; 26(6B):4585-9. PubMed ID: 17201181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
    Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H
    J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
    Cooper M; Tsai X; Bennett P
    Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of masitinib mesylate in healthy cats.
    Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
    J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
    Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
    J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.
    Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA
    Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.